Aquestive Therapeutics, Inc. (AQST) Financials

AQST Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 57.4 million 163.9 million
2023-09-30 59.4 million 162.4 million
2023-06-30 57.0 million 163.6 million
2023-03-31 61.3 million 170.5 million

AQST Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -5.0 million 940000
2023-09-30 -2.5 million 774000
2023-06-30 -8.7 million 631000
2023-03-31 8.8 million 344000

AQST Net Income

No data available :(

AQST Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 23.9 million - 5.8 million
2023-09-30 24.9 million - 5.9 million
2023-06-30 22.4 million 20.8 million 6.0 million
2023-03-31 26.9 million 25.2 million 6.0 million

AQST Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 68.5 million
2023-09-30 64.7 million
2023-06-30 57.4 million
2023-03-31 73.8 million

AQST Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 16000 2.9 million 9.6 million -
2023-09-30 151000 3.2 million 7.4 million -
2023-06-30 826000 3.5 million 7.4 million -
2023-03-31 2000 3.5 million 7.5 million -

AQST Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 13.2 million 4.7 million
2023-09-30 13.0 million 4.8 million
2023-06-30 13.2 million 6.6 million
2023-03-31 11.1 million 4.7 million

AQST

Price: $3.50

52 week price:
1.15
6.23

Earnings Per Share: -0.13 USD

P/E Ratio: -11.95

Exchange: NGM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Volume: 208846

Market Capitalization: 351.8 million

Links: